Education
About Us
Working with TipRanks
Follow Us
Arcturus Therapeutics (ARCT)
NASDAQ:ARCT
Earnings Data
Report Date
May 11, 2026After Close (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
-1.01Last Year’s EPS
-0.52Same Quarter Last Year
Moderate Buy
Based on 10 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The call presented a balanced picture: several program and platform positives (UK approval for Costave, ARCT-2304 durable immune responses, ARCT-032 advancing to a 12‑week Phase II, ARCT-810 moving toward pivotal discussions) alongside significant near-term financial and commercial challenges (material year-over-year revenue declines, reduced cash balance, ongoing CSL collaboration uncertainty, and early-stage clinical efficacy data in small cohorts). Management highlighted expense reductions and extended runway to Q2 2028, but commercial/regulatory clarity (especially in the U.S. for Costave) and larger clinical datasets are needed to materially de-risk the outlook.Company Guidance
UK Regulatory Approval for Costave
MHRA granted approval in January 2026 for Costave (self-amplifying mRNA COVID-19 vaccine) for individuals aged 18+, validating commercial/regulatory potential for the sa-mRNA platform.
ARCT-2304 (A/H5N1) Phase I Durable Immune Response
BARDA-funded ARCT-2304 completed Phase I in 212 younger adults and 80 older adults; 8-month follow-up showed durable immune responses across 1.5, 5 and 12 µg doses, with no safety concerns—supporting the STARR® sa-mRNA platform and cell-mediated immunity signal.
ARCT-032 (CF) Advancement to 12-Week Phase II
ARCT-032 progressed from 4-week dosing into a planned 12-week Phase II (initiating dosing H1 2026) enrolling up to ~20 Class I CF patients across U.S. and international sites; 15 mg dosing (4 patients) showed no safety concerns and 10 mg earlier cohort had early signals (4 of 6 subjects had reduced mucus plugs after 28 days).
ARCT-810 (OTC) Moving Toward Pivotal Development
ARCT-810 advancing toward pivotal development with intent to serve both late-onset adult OTC patients and young children with severe disease; Type C regulatory meetings scheduled H1 2026 to clarify paths for adult and pediatric indications.
Cost and Dose Flexibility / Manufacturing Headroom
Company retains dosing flexibility (10 mg chosen for upcoming cohort with ability to dose to 15 mg and historical dosing up to 27 mg) which allows balancing efficacy testing and cost-of-goods considerations (lower dose reduces manufacturing expense).
Operating Expense Reductions and Extended Runway
Annual R&D decreased by $83.0M and annual G&A decreased by $6.7M (quarterly R&D down $19.3M); disciplined refocus extended cash runway into Q2 2028, supporting near-term program milestones.
ARCT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
ARCT Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Mar 03, 2026 | $7.91 | $7.58 | -4.17% |
Nov 10, 2025 | $8.78 | $8.67 | -1.25% |
Aug 11, 2025 | $11.39 | $14.89 | +30.73% |
May 12, 2025 | $11.59 | $11.86 | +2.33% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Arcturus Therapeutics (ARCT) report earnings?
Arcturus Therapeutics (ARCT) is schdueled to report earning on May 11, 2026, After Close (Confirmed).
What is Arcturus Therapeutics (ARCT) earnings time?
Arcturus Therapeutics (ARCT) earnings time is at May 11, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ARCT EPS forecast?
ARCT EPS forecast for the fiscal quarter 2026 (Q1) is -1.01.
